Grufity logo
Grufity logo
VXRT

VXRT - Vaxart Inc Stock Price, Fair Value and News

$0.56-0.02 (-3.45%)
Market Closed as of 16 Jun 2026, 04:00 pm ET

81/100

VXRT

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

81/100

VXRT

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

VXRT Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

VXRT Price Action

Last 7 days

-5%

Last 30 days

-16.2%

Last 90 days

-16.2%

Trailing 12 Months

-18.6%

VXRT RSI Chart

VXRT Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

VXRT Valuation

Market Cap

140.0M

Price/Earnings (Trailing)

3.77

Price/Sales (Trailing)

0.55

EV/EBITDA

1.99

Price/Free Cashflow

9.46

VXRT Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

VXRT Fundamentals

VXRT Revenue

Revenue (TTM)

255.6M

Rev. Growth (Yr)

87.9%

Rev. Growth (Qtr)

-62.37%

VXRT Earnings

Earnings (TTM)

37.1M

Earnings Growth (Yr)

133.22%

Earnings Growth (Qtr)

-90.59%

VXRT Profitability

Operating Margin

82.75%

EBT Margin

14.67%

Return on Equity

39.42%

Return on Assets

20.6%

Free Cashflow Yield

10.57%

VXRT Investor Care

Shares Dilution (1Y)

5.78%

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)
Net sales
YearQ1Q2Q3Q4
2026255.6M---
202547.4M80.7M148.2M237.3M
20248.9M13.9M16.8M28.7M
2023834.0K2.1M4.1M7.4M
2022471.0K359.0K--
20211.6M1.2M1.2M892.0K
20207.4M7.8M7.6M4.0M
20198.1M7.5M7.7M9.9M
20185.0M3.8M3.2M4.2M
20179.0M8.9M8.9M5.8M
201612.8M9.3M9.2M9.1M
201535.6M24.6M25.6M13.4M
201469.5M68.7M57.7M46.6M
201324.9M33.6M44.4M52.5M
201214.0M10.9M11.2M19.5M
201130.4M29.3M18.1M16.1M
2010---35.0M
Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)

About Vaxart Inc

VXRT
Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase II clinical trial with bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains; seasonal influenza vaccine, which is in Phase II clinical trial for the treatment of H1 influenza infection; respiratory syncytial virus vaccine, an oral vaccine platform, which is in preclinical stage; coronavirus vaccine, which is in Phase II clinical trial for the treatment of SARS-CoV-2 infection; human papillomavirus therapeutic vaccine that targets HPV 16 and HPV 18 for cervical cancers and precancerous cervical dysplasia. The company has license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.
 CEO
 WEBSITEhttps://vaxart.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES164

Vaxart Inc Frequently Asked Questions

VXRT is the stock ticker symbol of Vaxart Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Mon Jun 15 2026, market cap of Vaxart Inc is 140.02 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Mon Jun 15 2026, VXRT's PE ratio (Price to Earnings) is 3.77 and Price to Sales (PS) ratio is 0.55. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. VXRT PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Vaxart Inc has provided -0.283 (multiply by 100 for percentage) rate of return.